CN103476413B - 组合 - Google Patents

组合 Download PDF

Info

Publication number
CN103476413B
CN103476413B CN201280013896.6A CN201280013896A CN103476413B CN 103476413 B CN103476413 B CN 103476413B CN 201280013896 A CN201280013896 A CN 201280013896A CN 103476413 B CN103476413 B CN 103476413B
Authority
CN
China
Prior art keywords
compound
amino
base
administered
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280013896.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN103476413A (zh
Inventor
K.R.奥格
J.博茨福德-米勒
A.K.苏德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
University of Texas System
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd, University of Texas System filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Publication of CN103476413A publication Critical patent/CN103476413A/zh
Application granted granted Critical
Publication of CN103476413B publication Critical patent/CN103476413B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201280013896.6A 2011-01-26 2012-01-26 组合 Expired - Fee Related CN103476413B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161436435P 2011-01-26 2011-01-26
US61/436,435 2011-01-26
PCT/US2012/022638 WO2012103276A1 (en) 2011-01-26 2012-01-26 Combinations

Publications (2)

Publication Number Publication Date
CN103476413A CN103476413A (zh) 2013-12-25
CN103476413B true CN103476413B (zh) 2016-03-16

Family

ID=46581159

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280013896.6A Expired - Fee Related CN103476413B (zh) 2011-01-26 2012-01-26 组合

Country Status (13)

Country Link
US (2) US20130296356A1 (enExample)
EP (1) EP2667871A4 (enExample)
JP (1) JP2014503589A (enExample)
KR (1) KR20140011322A (enExample)
CN (1) CN103476413B (enExample)
AU (1) AU2012209100A1 (enExample)
BR (1) BR112013018565A2 (enExample)
CA (1) CA2825790A1 (enExample)
EA (1) EA201391076A1 (enExample)
IL (1) IL227377A0 (enExample)
MX (1) MX2013008654A (enExample)
SG (1) SG191926A1 (enExample)
WO (1) WO2012103276A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013123413A2 (en) * 2012-02-17 2013-08-22 Pharmacyclics, Inc. Combinations of histone deacetylase inhibitor and pazopanib and uses thereof
RU2015117483A (ru) * 2012-10-12 2016-12-10 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Комбинации
MX2015005114A (es) * 2012-10-22 2015-07-17 Glaxosmithkline Llc Combinacion.
EP2925728A4 (en) * 2012-11-27 2016-11-02 Glaxosmithkline Llc COMBINATION

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008115369A2 (en) * 2007-03-16 2008-09-25 The Scripps Research Institute Inhibitors of focal adhesion kinase
WO2009153589A1 (en) * 2008-06-17 2009-12-23 Astrazeneca Ab Pyridine compounds
WO2010036796A1 (en) * 2008-09-26 2010-04-01 Concert Pharmaceuticals, Inc. Pyridineamine derivatives
WO2010062578A1 (en) * 2008-10-27 2010-06-03 Glaxosmithkline Llc Pyrazolylaminopyridines as inhibitors of fak

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8034860B2 (en) * 2006-07-21 2011-10-11 Eastman Specialties Holdings Corporation Organosol plastisol compositions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008115369A2 (en) * 2007-03-16 2008-09-25 The Scripps Research Institute Inhibitors of focal adhesion kinase
WO2009153589A1 (en) * 2008-06-17 2009-12-23 Astrazeneca Ab Pyridine compounds
WO2010036796A1 (en) * 2008-09-26 2010-04-01 Concert Pharmaceuticals, Inc. Pyridineamine derivatives
WO2010062578A1 (en) * 2008-10-27 2010-06-03 Glaxosmithkline Llc Pyrazolylaminopyridines as inhibitors of fak

Also Published As

Publication number Publication date
IL227377A0 (en) 2013-09-30
KR20140011322A (ko) 2014-01-28
SG191926A1 (en) 2013-08-30
WO2012103276A1 (en) 2012-08-02
EA201391076A1 (ru) 2014-07-30
CA2825790A1 (en) 2012-08-02
EP2667871A4 (en) 2014-07-09
CN103476413A (zh) 2013-12-25
BR112013018565A2 (pt) 2016-09-27
MX2013008654A (es) 2013-09-02
EP2667871A1 (en) 2013-12-04
US20160067248A1 (en) 2016-03-10
AU2012209100A1 (en) 2013-08-01
US20130296356A1 (en) 2013-11-07
JP2014503589A (ja) 2014-02-13

Similar Documents

Publication Publication Date Title
JP5416328B2 (ja) 血管形成及び／又は増加した血管透過性に関連する疾病の治療におけるゲムシタビンと、そして場合により電離放射と組み合わせたキナゾリン誘導体ｚｄ６４７４の使用
CN103476413B (zh) 组合
JP2008514577A (ja) Ｚｄ６４７４及びイマチニブを含んでなる組合せ
AU2012257833A1 (en) Method for treatment of solid malignancies including advanced or metastatic solid malignancies
KR20250121432A (ko) Mta-협력 prmt5 저해제를 사용한 암 치료
TW202435855A (zh) 包含阿茲夫定的抗腫瘤藥物組合物
JP6546098B2 (ja) 組み合わせ処置
EP4196116B1 (en) Pharmaceutical composition comprising cabozantinib, plerixafor, afatinib and etoricoxib for use in the treatment or prophylaxis of nsclc without driver mutations
JP2021063014A (ja) 白血病治療薬
WO2021018310A1 (zh) 用于治疗非小细胞肺癌的氨基吡啶衍生物
JP2013142059A (ja) 腎細胞がん治療剤
US20170027938A1 (en) Combination
WO2024088192A1 (en) An aurora a inhibitor for use in treatments of cancers
EP2344156B1 (en) Therapeutic combination comprising an aurora kinase inhibitor and an antineoplastic agent
TWI813694B (zh) 抗腫瘤劑及腫瘤治療方法
CN106176757B (zh) 一种化合物与替吉奥联合在制备治疗增生性疾病中的药物中的用途
Arena et al. Stomatitis and EGFR-tyrosine kinase inhibitors: a review of current literature in 4353 patients
WO2025070603A1 (ja) 血液がんの新規併用療法
JP2013526613A (ja) 組合せ
JP2015534987A (ja) 組合せ
JP2014034533A (ja) Ｈｓｐ９０阻害剤とｅｇｆｒチロシンキナーゼ阻害剤の組み合わせ
WO2011152515A1 (ja) インドール化合物を含有する抗腫瘍剤
JP2015534986A (ja) 組合せ
JP2014034535A (ja) Ｈｓｐ９０阻害剤とｖｅｇｆｒチロシンキナーゼ且つｐｄｇｆチロシンキナーゼ阻害剤の組み合わせ
CN101217966A (zh) 通过azd2171和吉西他滨对癌症的联合治疗

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160316

Termination date: 20170126